The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Invesco Ltd.: Form 8.3 - Netscientific Plc

27 Nov 2018 12:44



Invesco Ltd.: Form 8.3 - Netscientific Plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Invesco Ltd.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree  NetScientific PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 26 November 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:  5p Ordinary GB00B9F4MT28
 InterestsShort positions
 Number %Number %
(1) Relevant securities owned and/or controlled: 15,536,967 19.77%   
(2) Cash-settled derivatives:        
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:       
TOTAL: 15,536,967 19.77%   

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

Purchases and sales
Class of relevant security Purchase/sale  Number of securities Price per unit
       

 (b) Cash-settled derivative transactions

Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
         

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii) Exercise

Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit
        

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable)
       

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 27 November 2018
Contact name: Philippa Holmes
Telephone number: 01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Invesco Ltd.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree  NetScientific PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 26 November 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:  5p Ordinary GB00B9F4MT28
 InterestsShort positions
 Number %Number %
(1) Relevant securities owned and/or controlled: 15,536,967 19.77%   
(2) Cash-settled derivatives:        
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:       
TOTAL: 15,536,967 19.77%   

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

Purchases and sales
Class of relevant security Purchase/sale  Number of securities Price per unit
       

 (b) Cash-settled derivative transactions

Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
         

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii) Exercise

Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit
        

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable)
       

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 27 November 2018
Contact name: Philippa Holmes
Telephone number: 01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.


Date   Source Headline
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report
29th Jul 20144:23 pmRNSNetScientific announces shareholder name change
23rd Jul 20148:27 amRNSNetScientific Invests in Breakout Labs Companies
21st Jul 201411:43 amRNSTR1 - Notification of Major Interest in Shares
11th Jul 201411:50 amRNSTR1 - Notification of Major Interest in Shares
4th Jul 20142:11 pmRNSNotification of Major Interest In Shares
2nd Jul 20147:00 amRNSResearch Programme in DNA Sequencing
9th Jun 20144:34 pmRNSNetScientific plc
20th May 20145:33 pmRNSResult of AGM
20th May 20147:00 amRNSAGM Statement
19th May 20147:00 amRNSAnnouncement of research agreement with Harvard
8th May 201410:18 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:00 amRNSNetScientific Partners with Breakout Labs
19th Mar 20147:00 amRNSPreliminary results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.